Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cardiorenal Risk Stratification Pilot Study (CRiSPS): Using FGF-23 as a Risk Stratification Biomarker in Patients With Heart Failure and Chronic Kidney Disease as a Predictor of 1-year Morbidity and Mortality Risk

NCT03628443 is registered in ClinicalTrials.gov with Coney Island Hospital, Brooklyn, NY as lead sponsor.

NCT NCT03628443
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03628443 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cardiorenal Risk Stratification Pilot Study (CRiSPS): Using FGF-23 as a Risk Stratification Biomarker in Patients With Heart Failure and Chronic Kidney Disease as a Predictor of 1-year Morbidity and Mortality Risk
Lead sponsor
Coney Island Hospital, Brooklyn, NY
Phase
Observational
Overall status
Unknown status
Start date
July 19, 2018
Completion date
December 31, 2019
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardio-renal syndrome, chronic kidney diseases, heart failure